Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 3 1Phase 1/2 1Phase 1 1

Status

Not yet recruiting 3Unknown 2Recruiting 1

Sponsor Class

OTHER 6INDUSTRY 3

Study Type

Interventional 6

Sponsor

Cancer Type

Tumor-Agnostic 3Thoracic 1Sarcoma 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 35Carcinoma, Non-Small-Cell Lung 32Colorectal Neoplasms 19Esophageal Squamous Cell Carcinoma 18Stomach Neoplasms 17Squamous Cell Carcinoma of Head and Neck 16Rectal Neoplasms 11Cholangiocarcinoma 11Head and Neck Neoplasms 10Small Cell Lung Carcinoma 9Lung Neoplasms 9Esophageal Neoplasms 9Triple Negative Breast Neoplasms 8Uterine Cervical Neoplasms 7Nasopharyngeal Carcinoma 7Urinary Bladder Neoplasms 6Recurrence 6Pancreatic Neoplasms 6Neoplasms 6Colonic Neoplasms 6Melanoma 5Hodgkin Disease 5Biliary Tract Neoplasms 4Adenocarcinoma of Lung 4Sarcoma 3Non-Muscle Invasive Bladder Neoplasms 3Neoplasm Metastasis 3NSCLC 3Locally Advanced Rectal Cancer 3Liver Neoplasms 3

Interventions

Surveys and Questionnaires 114Exercise 103Blood Specimen Collection 99Radiotherapy 67Gemcitabine 64Bevacizumab 57Standard of Care 56Cisplatin 55Cyclophosphamide 51Capecitabine 50Carboplatin 49Docetaxel 47pembrolizumab 46Dexamethasone 46Paclitaxel 45Interviews as Topic 43Oxaliplatin 40Magnetic Resonance Spectroscopy 39Fluorouracil 37Methods 36Irinotecan 36Therapeutics 33Drug Therapy 33Radiosurgery 31Nivolumab 30Erlotinib Hydrochloride 27Educational Status 26Everolimus 24Leucovorin 23Control Groups 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
OTHER × Neoplasms × tislelizumab × Clear all
NCT07119996 2025-08-13

Clinical Trial on the Protective Role of Vitamin B3 in Enhancing Immunotherapy for Bladder Cancer Patients

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 1 Not yet recruiting
12 enrolled
Genitourinary

Urinary Bladder Neoplasms, Neoplasms

NCT06332274 2025-05-13

UMBRELLA

Gustave Roussy, Cancer Campus, Grand Paris

Phase 3 Recruiting
717 enrolled
GastrointestinalSarcomaThoracic

Colonic Neoplasms, Lung Neoplasms, Neoplasms, Pancreatic Neoplasms, Sarcoma

NCT06456138 2024-06-13

Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC

Shanghai Chest Hospital

Phase 1/2 Not yet recruiting
60 enrolled
Tumor-Agnostic

Neoplasms

NCT06363708 2024-04-12

Tislelizumab in Combination With Chemotherapy as a Neoadjuvant Treatment for Advanced Endometrial Cancer

Zhongnan Hospital

Phase NA Not yet recruiting
20 enrolled
Gynecologic

Neoplasms, Endometrial Neoplasms

NCT04985721 2023-03-15

IMPARP-HRD

Peter MacCallum Cancer Centre, Australia

Phase 2 Unknown
60 enrolled
Tumor-Agnostic

Neoplasms

NCT05241132 2022-02-15

Tislelizumab Combined With Chemotherapy in the Treatment of Bone Metastases of Unknown Primary

Shanghai Changzheng Hospital

Phase 2 Unknown
27 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡